The endocannabinoid system, part of the onboard cell-signaling system in mammals, has a clear role to play in substance-abuse disorders. On the evidence of animal models, this may extend to methamphetamines, where it is posited that the addiction process may be mediated by arachidonic acid cascade. In rats, 3,4 Methylenedioxymethamphetamine-conditioned place preference changes onpre-treatment with the experimental CB1 receptor antagonist 141716A.In rats trained to self-administer methamphetamine, intake has also significantly decreased with antagonist AM 251 pre-treatment, in a dose-dependant manner. Finally, pretreatment with ORG27569, a negative CB1 allosteric modulator, has also resulted in a dose-related attenuation of cue- and drug-induced reinstatement of methamphetamine-seeking behavior. It is not unreasonable to think that cannabidiol (CBD) could function in a future pharmacological therapy in methamphetamine abuse. CBD counteracts amphetamine-induced neuronal sensitization of the mesolimbic dopamine pathway, through a mTOR/p70S6 kinase signaling pathway. 

DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome.